Friday, June 21, 2013

Justice for Karina Hansen: A template for writing letters to Danish government officials


Letter Writing Template for Denmark officials

by Justice for Karina Hansen (Notes) on Wednesday, June 12, 2013 at 6:13pm

  • To use this template just copy and paste it into your own document. There are two items you will need to fill in. They are in bold and italicized to help you find them. One is a place for you to enter your own ME experience and the other is your signature at the bottom. Thank you for helping Karina Hansen and her family!


Dear Sir or Madam:

 I am writing to you concerning the treatment being offered in Denmark to those suffering from myalgic encephalomyelitis (ME).  In case you are unfamiliar with ME, it is a debilitating physical illness that has been classified as a neurological illness by the World Health Organization since 1969.

It has been brought to my attention that a young woman with myalgic encephalomyelitis named Karina Hansen has been forcibly removed from her home on February 12, 2013 for treatment she did not choose.

Karina is at Hammel Neurocenter and being treated by Nils Balle Christensen, a psychiatrist with The Research Clinic for Functional Disorders and Psychosomatics.  Karina's parents have not been allowed to visit her despite the fact it is not permitted to prevent relatives from visiting their family members in the hospital in Denmark.  It is my understanding that human rights are to be given the highest priority.

You can find more details regarding Karina Hansen's situation at ME Association, Denmark's Facebook page at https://www.facebook.com/meforeningen.dk/notes and http://tinyurl.com/nmvpgkn
.

This situation prompts many people around the world to ask:
1. Does Denmark recognize the World Health Organization code for ME?

Please note that benign myalgic encephalomyelitis is coded as G93.3 in the chapter entitled "Diseases of the Nervous System" under the subheading "Other disorders of brain."  To further clarify, myalgic encephalomyelitis is listed under diseases of the nervous system and NOT mental and behavioural disorders.
It is my understanding that any country that accepts the WHO Regulations for nomenclature is obligated to accept the ICD classification.   If Denmark accepts the ICD classification of ME as a neurological illness, than why are doctors who specialize in mental and behavioural disorders in charge of an ME patient's treatment?

2. What is the recommended treatment for ME patients in Denmark?

Myalgic encephalomyelitis can result in death without proper treatment. One well-known case is that of Sophia Mirza in England. You can find more information about her death at  http://investinme.org/Article-050%20Sophia%20Wilson%2001-RIP.htm
 
                  .
3. Do ME patients in Denmark not have the right to choose which treatment to receive? Also do they not have the basic human rights of visitation with their family?

4. Who monitors experimental treatments to be certain that no basic human rights are being denied in cases such as these?

In order to help you understand the many challenges someone with ME faces, I would  like to share my personal experiences of dealing with ME.  (Please add your personal experience with ME and possibly any problems you have suffered resulting from any wrong treatment you have received)

Many people around the world are concerned with Karina Hansen's treatment and have signed petitions in support of her. They can be found at change.org   http://tinyurl.com/p55nxdp
 , causes.com http://tinyurl.com/au3c7t4
  and ipetition.com  http://www.ipetitions.com/petition/postcardtokarina/
  .
A video has also been made to spread awareness of what Karina is facing and can be seen here athttp://www.youtube.com/watch?v=Dk3e8IWj7M0
 .
All of these things show that Karina Hansen and her family have a world of support!

 I ask that you please do all within your power to have Karina Hansen's human rights restored and see that she has proper treatment for myalgic encephalomyelitis.

I understand you cannot answer any questions about Karina Hansen's case, but I would appreciate answers to the general questions about the treatment of ME patients in Denmark.


  I would appreciate your prompt attention to the matter. Thank you for your consideration.

                                                                  Sincerely,
                                                                        (your name)



Danish Health and Medicines Authority (Sundhedsstyrelsen)
Axel Heides Gade 1
2300 Copenhagen S
Denmark
Email: sst@sst.dk
Telephone: +45 7222 7400 Monday to Friday, 9:30 - 15:00.

Danish regional Office:
Statsforvalningsen Midtjylland
St. Blichers Vej 6
Postbox: 151
6950 Ringkobing

midtjylland@statsforvaltning.dk
Tele: +45 7256 8300

County Office:
Holstebro County - Mayor’s Office
Rådhuset
Kirkestræde 11
7500 Holstebro

Tlf. 9611 7500
kommunen@holstebro.dk



Psychiatrists Abuse their power, Karina Hansen Sectioned for No reason

Tuesday, June 11, 2013

BIG MULTIPLE SCLEROSIS BREAKTHROUGH: first treatment to reset the immune system


Phase 1 trial safely resets patients’ immune systems, reduces attack on myelin protein

June 4, 2013 | by Marla Paul:

CHICAGO --- A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and dramatically reduced patients’ immune systems’ reactivity to myelin by 50 to 75 percent, according to new Northwestern Medicine research.

In MS, the immune system attacks and destroys myelin, the insulating layer that forms around nerves in the spinal cord, brain and optic nerve. When the insulation is destroyed, electrical signals can’t be effectively conducted, resulting in symptoms that range from mild limb numbness to paralysis or blindness.

“The therapy stops autoimmune responses that are already activated and prevents the activation of new autoimmune cells,” said Stephen Miller, the Judy Gugenheim Research Professor of Microbiology-Immunology at Northwestern University Feinberg School of Medicine.  “Our approach leaves the function of the normal immune system intact. That’s the holy grail.”

Miller is the co-senior author of a paper on the study, which was published June 5 in the journal Science Translational Medicine. The study is a collaboration between Northwestern’s Feinberg School, University Hospital Zurich in Switzerland and University Medical Center Hamburg-Eppendorf in Germany.

The human trial is the translation of more than 30 years of preclinical research in Miller's lab.  

In the trial, the MS patients’ own specially processed white blood cells were used to stealthily deliver billions of myelin antigens into their bodies so their immune systems would recognize them as harmless and develop tolerance to them.  

Current therapies for MS suppress the entire immune system, making patients more susceptible to everyday infections and higher rates of cancer.

While the trial’s nine patients -- who were treated in Hamburg, Germany -- were too few to statistically determine the treatment’s ability to prevent the progression of MS, the study did show patients who received the highest dose of white blood cells had the greatest reduction in myelin reactivity.

The primary aim of the study was to demonstrate the treatment’s safety and tolerability. It showed the intravenous injection of up to 3 billion white blood cells with myelin antigens caused no adverse affects in MS patients. Most importantly, it did not reactivate the patients’ disease and did not affect their healthy immunity to real pathogens.

As part of the study, researchers tested patients’ immunity to tetanus because all had received tetanus shots in their lifetime. One month after the treatment, their immune responses to tetanus remained strong, showing the treatment’s immune effect was specific only to myelin.  

The human safety study sets the stage for a phase 2 trial to see if the new treatment can prevent the progression of MS in humans. Scientists are currently trying to raise $1.5 million to launch the trial, which has already been approved in Switzerland. Miller’s preclinical research demonstrated the treatment stopped the progression of relapsing-remitting MS in mice.

“In the phase 2 trial we want to treat patients as early as possible in the disease before they have paralysis due to myelin damage.” Miller said.  “Once the myelin is destroyed, it’s hard to repair that.”

In the trial, patients’ white blood cells were filtered out, specially processed and coupled with myelin antigens by a complex GMP manufacturing process developed by the study co-senior authors, Roland Martin, Mireia Sospedra, and Andreas Lutterotti and their team at the University Medical Center Hamburg-Eppendorf. Then billions of these dead cells secretly carrying the myelin antigens were injected intravenously into the patients. The cells entered the spleen, which filters the blood and helps the body dispose of aging and dying blood cells. During this process, the immune cells start to recognize myelin as a harmless and immune tolerance quickly develops. This was confirmed in the patients by immune assays developed and carried out by the research team in Hamburg.

This therapy, with further testing, may be useful for treating not only MS but also a host of other autoimmune and allergic diseases simply by switching the antigens attached to the cells. Previously published preclinical research by Miller showed the therapy’s effectiveness for type 1 diabetes and airway allergy (asthma) and peanut allergy.

The MS human trial relates directly to Miller’s recently published research in mice in which he used nanoparticles -- rather than a patient’s white blood cells -- to deliver the myelin antigen. Using a patient’s white blood cells is a costly and labor-intensive procedure. Miller’s study showed the nanoparticles, which are potentially cheaper and more accessible to a general population, could be as effective as the white blood cells as delivery vehicles.  This nanoparticle technology has been licensed to Cour Pharmaceutical Development Company and is in preclinical development.

Miller’s research represents several pillars of Northwestern’s Strategic Plan by discovering new ways to treat disease in the biomedical sciences and translating those discoveries into ideas and products that make the world a better place for everyone.

The research was supported by the German Federal Ministry for Education and Research and the Cumming Foundation.

Thursday, June 6, 2013

Special award for Professor Malcolm Hooper !!!




Professor Malcolm Hooper - with Ellen Piro and Eva Stormorken of the Norwegian ME Association - being presented with his special award for his tremendous work for ME over the years. En flott gest fra Norge!
 — at IIMEC8 - 8th Invest in ME International ME Conference 2013.


Tuesday, June 4, 2013

Synopsis of the 8th International Invest in ME Conference, 31st May 2013, by Dr William Weir


Notes made by Dr William Weir at the 8th Invest in ME Conference, May 2013.

Permission to repost.

INVEST IN ME

Synopsis of proceedings of 8th International Conference held on 31st May 2013. Dr William Weir FRCP (Lond) FRCP (Edin)

The main theme of this conference focused on the three burning questions which all ME sufferers want answered, namely what causes ME, what is being done to discover this cause and what treatments might be effective? What was very encouraging was the impressive cast of speakers from around the world whose scientific credentials could not be challenged. Happily, none of them were psychiatrists, as gradually the psychiatric, biopsychosocial theory of ME causation is being consigned to the dustbin of history. There is now far too much high quality scientific evidence indicating that ME is due to immunological dysfunction and many of the speakers stated this principle very forcefully.

There were four main categories of speaker. Firstly there were those who talked about the organization of studies, which included the collection and computerisation of data (such as case histories) and biological material (such as blood and other body fluid samples). Clearly, in the USA at least, work of this nature is now getting off the ground and a large effort is being made to establish a “biobank” of biological materials from patients which will be made available to researchers. Here in the UK a biobank has already been set up, based at the London School of Hygiene and Tropical Medicine to where blood samples are being sent for cold storage. 

Secondly there were the immunologists who described the immunological abnormalities seen in ME patients. One of the frustrations with ME is that, although there are always across-the-board abnormalities, those seen are never as consistent as they are, for example in AIDS where one particular type of immunologically active cell is consistently reduced. However one of the speakers came out with the opinion that: “if any doctor now thinks that these abnormalities are due to psychological disorder and that exercise is the cure, he/she should be deregistered” (He was from Australia). 

One phenomenon which is now well recognised is the “cytokine flare” which follows physical (and mental) exercise. Cytokines are substances produced by the immune system as part of a normal immune response to the presence of an invading bug, be it a virus or bacterium (or other, such as a malaria parasite). Interferon is the one most people have heard of. They make you feel ill as part of the body’s normal defence against infection. In ME however they appear to be produced inappropriately, and go on being produced in the apparent absence of a recognisable infection. Furthermore there is an abnormal increase - “flare” - after exercise which now explains the problem of post exertional malaise. Here, at last, is direct evidence that Graded Exercise Therapy (GET) is very likely to be harmful.

Thirdly the issue of a possible virus infection was addressed. This would provide a logical explanation for the ongoing immunological activity – finally identifying the metaphorical fire from which all the immunological smoke was coming. The XMRV story was reviewed and provided real insights into the complexities of identifying a “new” virus. The term “new” meaning hitherto undiscovered, as it is fully appreciated that there are probably very many undiscovered viruses out there in the biological ecosystem, often being carried silently (ie without illness) by a large range of animals, including humans. The disease -causing potential of these viruses is unknown and may have very long incubation periods with infection preceding the development of disease by many years. For example It has been suggested that Parkinson’s disease is due to such a virus, and the same may be true of ME.


As many will know, XMRV was finally recognised as a contaminant of the cultures in which attempts were being made to grow a new virus from samples taken from ME patients. The initial excitement over the discovery of XMRV was dampened when this was realized, but has not deterred the search for other viruses. To apply historical perspective, when influenza was first researched, a number of bacteria and viruses were initially but incorrectly proposed as the cause before the real villain was identified. Some very sophisticated techniques are now being used in the search for the real ME villain, one candidate being a form of retrovirus known as a “human endogenous retrovirus” (HERV). These are viruses which are already present in human genes, and usually inactive (ie not replicating). Nonetheless they probably can be turned on again and they have been postulated as causes of a wide range of diseases, including cancer and autoimmune disease. Thus ME may well be due to a HERV. 

Finally there was a presentation of the Norwegian study of rituximab therapy which shows promise in the treatment of ME. Twenty of twenty eight patients improved significantly although there was a lag period of two to three months before improvement occurred. Rituximab specifically targets the CD20 lymphocytes, taking them out of circulation but well before symptomatic improvement – suggesting that it is antibodies produced by the CD20 cells which cause the symptoms, but which require the 2-3 month period to clear from the body. This study on its own supports the immunological hypothesis of causation, 
further diminishing the psychiatric attribution of an “abnormal illness belief”.

Rituximab does however have its drawbacks. It is potentially very toxic, also very expensive and no UK doctor would be able to prescribe it for ME at present. Further studies are in progress.

Watch this space!

Tuesday, May 28, 2013

Research suggests that Antibodies from abnormal lymphocytes are blocking the aerobic energy production in muscle and brain cells in ME

Numerous research papers have shown immune abnormalities in ME. Combined with:

See also: Study demonstrates that 95% of ME/CFS Patients have Anticardiolipin Antibodies, suggesting that ME/CFS may be an autoimmune condition

See also: Prof Behan on BBC ALBA: electron microscopy shows abnormal mitochondria in Myalgic Encephalomyelitis, and we have known this since the 1980s

See also: The main characteristic of ME is an abnormally delayed muscle recovery after doing trivial things, if you don't have that, you don't have ME 

See also: Oncologist Professor Mella: Rituximab treatment suggests that ME/CFS is an autoimmune disease

See also: Marked recovery of CFS symptoms during methotrexate treatment

See also: Altered functional B cell subset populations in patients with ME/CFS compared to healthy controls

See also: Professor Simon Wessely: A man has got to know his limitations and my limitations are immunology and ME/CFS
See also: The delayed responses starting from 2–7 months after Rituximab treatment, in spite of rapid B-cell depletion, suggests that CFS is an autoimmune disease and may be consistent with the gradual elimination of autoantibodies preceding clinical responses.

See also: Discovermagazine April 2013: Are B-Cells to Blame for Chronic Fatigue Syndrome? 

See also: Professor Simon Wessely: the primary symptom of ME is post-exertional muscle fatigability not fatigue

See also: Professor Julia Newton: aerobic energy production in muscle cells in ME is blocked 

and Combined with my Lactic acid ME muscle symptoms Research suggests that Antibodies from abnormal lymphocytes are blocking the aerobic energy production in muscle and brain cells in ME.

Is this what causes ME ?

Tuesday, May 21, 2013

Dr. Maria Gjerpe’s CBT for ME/CFS: Crowdfunding B-Cell Treatment

Dr. Maria Gjerpe, an ME patient for 30 years, explains how and why MEandYou are going to crowdfund a Rituximab study:

Within 90 days we are going to raise 7 million Norwegian krone ($1.2 million) to fund a study on 140 ME/CFS patients at Haukeland Hospital in Bergen, Norway.

Will we – the patients, relatives, friends – be the first in the world to crowdfund a clinical trial? And can we engage both sides of the Atlantic to make it happen? Yes!

In 2011, a study at Haukeland Hospital on the use of the immunosuppressive medication Rituximab against ME attracted international attention. Two-thirds of the patients in the study experienced significant improvement after being treated with the drug.
Read more>>

Friday, May 17, 2013

Psychiatrists Abuse their power, Karina Hansen Sectioned for No reason

Posted on May 11, 2013 by admindxrw:

Something rotten in the state of Denmark:

Karina Hansen’s story


Karina Hansen is 24. She has been completely bedridden since 2009.

In February, this year, Karina was forcibly removed from her home and committed to a hospital. The family is still waiting for a legal explanation for why she was removed.

Karina suffers from severe ME and her family believes she is getting worse.

Karina removed from home

On February 12, 2013, five policemen from Holstebro county, Denmark, arrived at Karina’s house and forcibly removed her from her bed.

Two doctors, a locksmith and two social workers were also present.

Karina called for her mother’s help, but her mother was blocked by the police from aiding her. Karina used her mobile phone for the first time in years to call her mother, her father, her cousin and her sister, Janni. Karina is so ill that she can usually only speak in one or two word sentences, but during her removal she managed to call her father and say: Read more>>

Sunday, May 12, 2013

May 12th: Niagara Falls Goes Blue for ME/CFS

 

Mark takes a look at what’s going on around the world this weekend to mark International Awareness Day, phoenixrising.me:

Niagara Falls Goes Blue

Where: Niagara Falls, Canada

When: May 12, 9:45 to 10:00 PM EST

The May 12th ME/FM Facebook page team have arranged to have Niagara Falls lit up with ME/FM colours. The Niagara Parks Commission of Niagara Falls Canada has confirmed that Niagara Falls will be illuminated in blue from 9:45 to 10:00 PM EST representing Myalgic Encephalomyelitis, and illuminated in purple from 10:15 to 10:30PM EST representing Fibromyalgia. The event can be watched live on the falls webcam.

May 12th is International Awareness Day for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).

Awareness Day events also recognize Fibromyalgia (FM), Multiple Chemical Sensitivities (MCS), Gulf War Syndrome (GWS), Lyme Disease, and other chronic neuro-endocrine-immune diseases (NEIDs). Awareness Week runs from May 12th-18th, and the whole of May is Awareness Month. As with many awareness campaigns, ribbons are worn to show support for the campaign – blue for ME/CFS, purple for FM, and green for MCS.


Read more>>

Tuesday, May 7, 2013

Professor Simon Wessely: the primary symptom of ME is post-exertional muscle fatigability not fatigue

 

Malcolm Hooper and Margaret Williams 5th May 2013:

Sensationalism versus Science?

Malcolm Hooper and Margaret Williams       5th May 2013


The long-promised article by Michael Hanlon on the “war” surrounding the neuroimmune disorder myalgic encephalomyelitis (ME) was published today in the Sunday Times Magazine together with a photograph of Professor Sir Simon Wessely (“This man faced death threats and abuse.  His crime? He suggested that ME was a mental illness”). Whilst the article focuses on the unacceptable actions of very few alleged sufferers and not on legitimate challenges mounted by scientists, it may be of interest to reproduce the questions which Hanlon sent to Professor Malcolm Hooper on 31st January and also Professor Hooper’s reply, since that reply provides the backdrop to the on-going “war”.

First, though, it must be said that much of Hanlon’s article is factually wrong. For example, Hanlon begins his article with the assertion that “Professor Sir Simon Wessely lives on the front line of science”,which immediately reveals a lack of understanding in that Sir Simon does not live on the front line of biomedical science but on the front line of psychiatry, a discipline with no biomarkers of disease. Indeed Sir Simon ignores, actively denies or dismisses the evidence of biomedical scientists that demonstrates whole-body inflammation in ME and does not accept that it has now been shown to be an autoimmune disease.

Hanlon goes on to state that Sir Simon “has done a lot of work for the military, helping to treat traumatised war veterans”, when there is irrefutable published evidence that Sir Simon has for decades denied the very existence of Gulf War Syndrome.

Hanlon then states that ME “affects about 600,000 people in Britain”, an assertion not supported by the 2002 Report of the UK Chief Medical Officer, which found there to be about 250,000 sufferers in the UK, of which 25% are severely affected, being house or bed-bound.  However, conflating “chronic fatigue” with ME would certainly increase the numbers of alleged sufferers, but lacks scientific credibility.

Hanlon states that “The primary symptoms of the disease is fatigue”; this, again, is inaccurate, because the primary symptom of ME is post-exertional muscle fatigability, this being the cardinal symptom of ME and quite different from fatigue or tiredness.

Hanlon goes on to state that “Most doctors who treat ME…believe that …cognitive behavioural therapy and exercise therapies provide the best hope for many sufferers to get better” but Hanlon does not explain that in general in the UK, the only doctors who treat ME are psychiatrists or those who work for the permanent health insurance industry, who adhere to their own now-disproven theory that ME is a behavioural disorder and thus does not qualify for insurance payments, neither does he mention the findings in a survey of 2,338 ME sufferers that “Graded exercise was reported to be the treatment that had made most people worse” or the further findings that 93% of respondents found GET to be unhelpful, with 82% reporting that their condition was made worse (http://www.meactionuk.org.uk/magical-medicine.htm).

Hanlon claims that these doctors are in the majority without telling his readers the reason, which is that for over 25 years, as well as acting as advisors on ME/CFS to Departments of State and the insurance industry, Sir Simon and his colleagues have flooded the literature with their own beliefs, to the extent that any doctor who opposed them would be in real jeopardy of losing his/her job and of being labelled naïve and unable to deal effectively with suggestible patients (Simon Wessely.  Psychological Medicine 1990:20:35-53). It takes a courageous clinician to risk running such a gauntlet.

Whilst not mentioning the PACE trial by name, Hanlon refers to “a ground-breaking paper” which he claims shows that CBT and exercise therapies provide the best hope for many sufferers to get better, a trial over which Sir Simon is known to swoon: “For those who appreciate these things, the trial is a thing of beauty” (Health in mind and body.  Simon Wessely. The Journal of the Foundation for Science and Technology, Volume 20, Number 7, December 2011) even though the Investigators themselves acknowledge that it was “only moderately effective”.

Hanlon mentions a new initiative – the UK CFS/ME Research Collaborative launched on 22nd April 2013 – of which Dr Esther Crawley seems to be in charge, but he does not mention that the Collaborative Charter stipulates that membership is open only to those who agree to the Collaborative’s  insistence that “(3.2.3) Members will be required to sign a declaration that they will not take part in the harassment or abuse of researchers. Neither will they take part in orchestrated campaigns against those conducting peer-reviewed research”.  Does this mean that the charities who have signed up to the Collaborative will be prevented from legitimate disagreement with the aims and objectives of the Collaboration?  The press release hosted on the website of Action for ME states categorically that“Predisposing factors include female sex, functional somatic syndromes, and prior mood disorders” even though the Medical Research Council itself now acknowledges that there is evidence of inflammation in the brain and spinal cord.  Will any legitimate disagreement continue to be construed as “harassment”?

Could these stipulations be the reason why, at the recent US FDA Stakeholder meeting held on 25th-26th April 2013 at which the PACE trial was discussed by world-renowned biomedical experts, Dr Peter Rowe said: " … and here is where I need my uniformed colleagues to provide me with some help because anyone who ventures into discussion of the PACE Trial probably needs an armed guard [.......]  I suspect that most of my clinician colleagues in the room would agree with this comment and that is that if all you've been able to do with your treatment is change your fatigue score by three points on a thirty-three point scale over a year, that that's the kind of thing that would have made us hang up our licenses and our office headings and quit CFS in frustration, we usually do better than that ...".  Dr Rowe was followed by Dr Christopher Snell, who also alluded to the parody being played out in the UK at the expense of severely sick people:  " ... so both Peter and I will need an armed guard when we leave, because I'm also going to talk a little bit about the PACE Trial...".

Hanlon had the opportunity to provide balance by using comments from informed commentators whose opinion he had canvassed: he opted instead to quote an unfortunate patient who is a self-admitted alcoholic who had been struck off the Veterinary Register and who has a conviction for indecent assault on a 12-year old girl. This person is hardly representative of the quarter of a million sufferers with ME in the UK: was this a deliberate attempt by Hanlon to smear the entire ME patient population?

Perhaps the most telling sentence in Hanlon’s article is this: “As for the 2009 XMRV paper, Wessely snorts with derision”.  It is this derision and absolute triumphalism over the XMRV debacle that personifies the way people with ME have been – and still are – treated. Indeed, the Wessely School have advised that the first duty of the doctor is to avoid legitimisation of symptoms (The MRC’s own summary of the CIBA Foundation Symposium on CFS held on 12-14th May 1992).

In 1994, one of the world’s most renowned ME/CFS clinicians, Dr Daniel L Peterson from the US, went on record: “In my experience, it is one of the most disabling diseases that I care for, far exceeding HIV disease except for the terminal stages” (Introduction to Research and Clinical Conference, Fort Lauderdale, Florida, October 1994; published in JCFS 1995:1:3-4:123-125).

In 1995, Professor Mark Loveless, Head of the AIDS and ME/CFS Clinic at Oregon Health Sciences University said in his Congressional Briefing that an ME/CFS patient: “feels effectively the same every day as an AIDS patient feels two weeks before death; the only difference is that the symptoms can go on for never-ending decades”.

In 2004, Dr William Reeves, Chief of the ME/CFS research programme at the US Centres for Disease Control, (CDC) reported that ME/CFS patients “are more sick and have greater disability than patients with chronic obstructive lung or cardiac disease, and that psychological factors played no role” (Press Release, AACFS, 7th October 2004).

Also in 2004, a randomised clinical trial found “In comparison with other chronic illnesses such as multiple sclerosis, end-stage renal disease and heart disease, patients with (ME)CFS show markedly higher levels of disability” (Am J Occup Ther 2004:58:35-43).

On 15th October 2009, Professor Nancy Klimas, then Professor of Medicine, Microbiology and Immunology at the University of Miami, famously said in the New York Times: “I hope you are not saying that (ME)CFS patients are not as ill as HIV patients.  I split my clinical time between the two illnesses, and I can tell you that if I had to choose between the two illnesses I would rather have HIV”

Wessely has long trivialised a devastating disorder from which people die, referring to it as a “myth”: the recent tragic deaths from ME of three young women in the UK, all in their 30s (Sophia Mirza, Lynn Gilderdale and Emily Collingridge) should shame all “non-believers”, including Sir Simon.

As one eminent UK consultant physician -- who bravely stands firm against the doctrine of Sir Simon --commented on Hanlon’s article: “No-one has apparently perceived the whole psychiatric paradigm as dogma, not science”.

Professor Hooper’s reply to Hanlon’s questions, sent to him on 5th February 2013, is reproduced below:


Dear Mr Hanlon

I notice that your couple of questions has multiplied to six which I will deal with in numerical order as best I can, although I am but one of very many national and international opponents of the PACE trial.

1.  Is it true, as Peter White asserts, that after the 2011 publication of the PACE trial you wrote several hundred pages of criticism to both the Lancet and the GMC?

No; it is not true.  You have been misinformed.  

In February 2010, before the PACE trial paper was published in The Lancet, together with many others I wrote “MAGICAL MEDICINE: HOW TO MAKE A DISEASE DISAPPEAR -- Background to, consideration of, and quotations from the Manuals for the Medical Research Council’s PACE Trial of behavioural interventions for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis, together with evidence that such interventions are unlikely to be effective and may even be contra-indicated”.  It is a 442 page report and was sent to the Medical Research Council, who dismissed most of it but conceded some of it.  I also sent it to Professor Sir Michael Rawlins, Chairman of NICE, whom I know personally, having worked with him in the past, but who returned it unread.

In March 2011, after publication of the PACE trial paper in The Lancet and the accompanying Comment by Bleijenberg and Knoop, I submitted a formal complaint amounting to 46 pages to The Lancet; the senior editor confirmed in writing that the Comment was erroneous and should be corrected, but the rest of the complaint was dismissed after interventions by Professor Peter White.

On 26th April 2010 I lodged a formal complaint to the GMC about Dr William Trevor Hamilton, chief medical officer of three insurance companies, because we have evidence that he knowingly misled the High Court in the Judicial Review of the NICE Clinical Guideline on CFS.  He was reprimanded by the GMC who, for the record, are still willing to pursue the matter.

2.  What, in essence (and not several hundred pages please!) was your objection? To the existence of the trial itself? To its findings? To the way it was conducted?

The PACE Trial  -- which cost £5 million --  I have described as a travesty of science and a tragedy for patients; the conclusions were flawed; the primary outcome measures were dropped; ratings that would qualify a participant as sufficiently impaired to enter the trial were deemed by the Principal Investigators to be “within the normal range” when recorded on completion of the trial; there were significant conflicts of interest in that all three PIs work for the insurance industry (whose managers insist that claimants undertake a course of CBT and GET --  called “rehabilitation” -- which, if people are too ill to do so or if they know from their own experience that it makes worse and therefore decline, payments are stopped on the basis that claimants do not to want to get better); the PIs intentionally studied a heterogeneous population and it was conceded only after publication of selective results in The Lancet that the Investigators did not purport to be studying ME but simply chronic “fatigue”; there was a failure to control the trial; there was downgrading of what constituted serious adverse events; there were many changes to the entry criteria; data was not reported and objective outcome measures were dropped; methods of scoring were changed so as to produce only minimally statistically better results that were blatantly misreported in The Lancet.

3.   What is your relationship, if any, to the ME campaigner Margaret Williams?

I am inclined to respond that this is none of your business, nor of your readers.  However, the truth is that we have known each other and worked together for many years on issues surrounding ME and GWS.  Margaret Williams formerly held a senior clinical post in the NHS. Together with an established team of clinicians and medical researchers, our aim is to expose and prevent the injustice perpetrated on patients with ME/CFS in the UK by those whose job is to help, not abuse or denigrate them. We are concerned about the current situation in the UK for people with ME/CFS and their carers who are seeking recognition of the extensive sound science that underlies the biomedical basis of the disease, the provision of an accurate diagnosis, a therapeutically useful intervention and appropriate care of patients.  ME/CFS is a devastating chronic multi-system, multi-organ disease which can be life-threatening; those who neither accept nor understand this should not be working in the field.

4.  Do you have ME yourself?

No.

5.  What sparked your involvement in this area?

I am Chief Scientific Advisor to the Gulf Veterans Association and President (since 2000) of the National Gulf War Veterans and Families Association.  I was increasingly being consulted by Gulf War veterans who had been diagnosed with ME accompanied with other “acronyms of ignorance” such as MUS (medically unexplained symptoms) and MUPS (medically unexplained physical symptoms), which led to my involvement with the wider issues surrounding ME/CFS.

6.   Do you support the continuing research into ME by people like White and Wessely and Crawley? Or do you think it should be stopped?

I do not support the work of Professors Peter White and Michael Sharpe, nor of Professor Sir Simon Wessely (in his case, not only with ME/CFS but with Gulf War Syndrome and his involvement with military health), nor of Dr Esther Crawley. There are several others, collectively known as “the Wessely School” in Hansard.

I do think it should be stopped.  I believe their work on ME/CFS to be seriously flawed, as it disregards the underlying pathology of the disease and may not even be looking at ME/CFS but at chronic fatiguethat can have many origins. The cardinal feature of ME is profound post-exertional malaise, also described as post-exertional neuroimmune exhaustion, ie. it is characterised by an inability to produce sufficient energy on demand.

In particular, the Wessely School’s long association with the insurance industry is a matter of concern, as noted by the report of Parliamentarians in 2006:

“At present, ME/CFS is defined as a psychosocial illness by the medical insurance companies. We recognise that if ME/CFS remains defined as psychosocial then it would be in the financial interests of the medical insurance companies.

“There have been numerous cases where advisors to the DWP have also had consultancy roles in medical insurance companies, particularly the company UNUMProvident. 

“Given the vested interest private medical insurance companies have in ensuring CFS/ME remains classified as psychosocial illness, there is blatant conflict of interest here.

“This Group finds this to be an area for serious concern and recommends a full investigation by the appropriate standard body”  (http://erythos.com/gibsonenquiry/Docs/ME_Inquiry_Report.pdf ).

Those parliamentarians who expressed this concern included the former Chairman of a House of Commons Science and Technology Select Committee and former Dean of Biology at the University of East Anglia; a member of the Home Affairs Select Committee; a Minister of State for the Environment; a former President of the Royal College of Physicians; the Deputy Speaker of the House of Lords, and a former Health Minister and Honorary Fellow of the Royal College of Physicians. To date, nothing whatever has been instituted to remedy this unacceptable situation.

I hope this reply will help you to compile a factual and fully representative article, which I look forward to reading.

Yours sincerely


Professor Malcolm Hooper


See also: Revalidation Update: why doctors who use or promote CBT or GET for ME/CFS will fail their revalidation
See also: The main characteristic of ME is an abnormally delayed muscle recovery after doing trivial things, if you don't have that, you don't have ME
See also: Another cracker from the CBT school of denial: “The bastards don’t want to get better”…

LinkWithin

Related Posts with Thumbnails